(ZTS) Zoetis - Ratings and Ratios

Zoetis Inc. (NYSE: ZTS) is a global leader in the animal health industry, specializing in the discovery, development, and commercialization of a wide range of products and services that improve the health and well-being of animals. The company operates across multiple species, including livestock such as cattle, swine, poultry, fish, and sheep, as well as companion animals like dogs, cats, and horses. Its product portfolio includes parasiticides, vaccines, dermatology products, anti-infectives, and medicated feed additives, all of which are critical for maintaining animal health and productivity.

Zoetis also offers a robust line of diagnostics, including point-of-care diagnostic products, instruments, reagents, rapid immunoassay tests, and reference laboratory kits and services. These tools enable veterinarians and livestock producers to make timely and accurate diagnoses, which is essential for preventing and managing diseases. Beyond pharmaceuticals, the company provides non-pharmaceutical products such as nutritionals, biodevices, genetic tests, and precision animal health solutions, demonstrating its commitment to a comprehensive approach to animal care.

The company collaborates with innovative partners like Blacksmith Medicines, Inc., to discover and develop novel therapeutics for animal health, further solidifying its position at the forefront of the industry. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey, with a strong global presence that spans the United States and international markets. Its website can be accessed at https://www.zoetis.com.

From a financial perspective, Zoetis Inc. is a significant player in the pharmaceutical sector, with a market capitalization of approximately $77.92 billion USD. The company trades on the New York Stock Exchange (NYSE) under the ticker symbol ZTS. Key financial metrics include a price-to-earnings (P/E) ratio of 32.40, a forward P/E of 29.41, a price-to-book (P/B) ratio of 14.67, and a price-to-sales (P/S) ratio of 8.51. These figures highlight Zoetis strong valuation and its position as a leading company in the animal health industry.